Lupus care shifts toward earlier, steroid-sparing treatment

KDIGO/KDOQI implementation guidance and the new ERN ReCONNET–SLICC–SLEuro consensus reinforce earlier recognition, combination therapy, reduced glucocorticoid exposure, and treat-to-target monitoring across common and rare SLE manifestations. Real-world cohort research is adding evidence on how standard medications relate to low disease activity, although details from the latest cohort remain limited.